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Background: Current antidepressants used to treat pediatric patients have the disadvantage of limited efficacy and
potentially serious side effects. The purpose of this study was to assess the efficacy of vitamin C as an adjuvant
agent in the treatment of pediatric major depressive disorder in a six-month, double-blind, placebo-controlled pilot
trial.
Methods: The study group (n=12) was given fluoxetine (10–20 mg/day) plus vitamin C (1000 mg/day) and control
group (n=12) administered fluoxetine (10–20 mg/day) plus placebo. The data were analyzed by ANOVA and t-test
for independent samples.
Results: Both groups demonstrated significantly improved scores on the Children’s Depression Rating Scale (CDRS),
the Children’s Depression Inventory (CDI), and the Clinical Global Impression (CGI). ANOVA was significantly different
on all clinical measurements (group effect, time effect, and interaction), with the exception of group effect and
interaction for CGI. Patients treated for six months with fluoxetine and vitamin C showed a significant decrease in
depressive symptoms in comparison to the fluoxetine plus placebo group as measured by the CDRS (t=11.36,
P<0.0001) and CDI (t=12.27, P<0.0001), but not CGI (t=0.13, P=0.90). No serious adverse effects were observed.
Conclusions: These preliminary results suggest that vitamin C may be an effective adjuvant agent in the treatment
of MDD in pediatric patients.Introduction
The prevalence of depression in community settings
has been estimated to be between 0.4% and 2.5% in
children and 0.4% and 8.3% in adolescents [1]. How-
ever, in a more recent community study of children
without depression who were initially assessed between
the ages of 9 and 13 years, more than 7% of boys and
almost 12% of girls developed a depressive disorder by
the age of 16 [2].
While the diagnosis of major depressive disorder
(MDD) in younger patients generally follows the criteria
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[3], the treatment of pediatric depression presents many
challenges. Not only do children with MDD have multiple
co-morbid disorders [4,5], psychosocial and academic
problems, and are at increased risk for suicide attempts,
self-harm, and substance abuse [1,6-10], treatment options
are often limited and ineffective, poorly tolerated, and
generally present long delays in delivering a therapeutic
benefit [11-14].
One of the few antidepressants approved for use in
children is the selective serotonin reuptake inhibitor
(SSRI) fluoxetine [15]. The first study that demonstrated
the positive effects of using fluoxetine to treat depres-
sion in child and adolescent patients was published in
1997 [16], following a small trial in which no difference
was observed between fluoxetine treatment and placebo
[17]. Overall, five clinical trials have been conducted. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treat pediatric depression [16,18-21]. In addition, the im-
provement response rate on the Clinical Global Impres-
sions (CGI) for antidepressant use was found to be
between 52% and 61% for fluoxetine patients versus 33%
to 37% for patients treated with placebo [22]. The CGI
measures whether or not depressive symptoms have im-
proved after treatment.
Despite being one of the most popular treatments for
pediatric patients, in 2004 the use of prescription medi-
cation such as fluoxetine as well as other antidepressant
medications declined by approximately 20% in the
United States [23]. This shift in prescription patterns is
likely due to warnings issued by regulatory agencies, ini-
tially in the United Kingdom [24] and later in the United
States [25], against the use of SSRIs to treat depression
in pediatric populations due to the possible link between
antidepressant usage and an increased incidence of sui-
cidal ideations or attempts. Subsequently, there is a
compelling need for better understanding of the patho-
physiology of MDD as well as the development of novel
treatment methods that can be used to improve the
current clinical management of pediatric depression.
Nutrients like vitamin C (ascorbic acid) have become
of interest in adjuvant therapy settings for the manage-
ment of depressive symptoms due to the fact that psy-
chological abnormalities are among the characteristics of
vitamin C deficiency [26-29]. A recent population-based
survey revealed that 60% of the patients in the acute
medical wards of a Montreal teaching hospital were vita-
min C deficient, while this deficiency was only detected
in 16% of people attending the hospital’s outpatient cen-
ter [30]. There is also preliminary evidence that the ad-
ministration of vitamin C may be able to reduce the
severity of MDD in both children [31] and adults [32],
as well as improve mood in healthy individuals [33-35].
In addition, a recent study reported a 35% reduction in
average mood disturbance in hospitalized patients fol-
lowing treatment with vitamin C (1000 mg/day) [36]. In
one particular study that investigated mood, patients
who were acutely hospitalized were either treated with
vitamin C or vitamin D as a deficiency in both of these
vitamins has been associated with psychological abnor-
malities [32]. The results showed that only vitamin C led
to an improved mood. More specifically, treating the
vitamin C deficiency led to a decrease in mood disturb-
ance while vitamin D supplementation had no effect on
mood. Similar findings were observed in non-critically ill
hospitalized patients who were treated with vitamin C
for hypovitaminosis C [36]. Moreover, an animal study
showed that the co-administration of vitamin C was
found to potentiate the action of subeffective doses of
fluoxetine (1 mg/kg) [37]. This synergistic antidepressant
effect of vitamin C and fluoxetine suggests that thisvitamin could be helpful in improving conventional
pharmacotherapy for pediatric MDD and potentially re-
duce side effects.
This study would be the first to examine the efficacy
of vitamin C as an adjunct to SSRIs in the treatment of
pediatric depression. In addition, the low potential tox-
icity, inexpensiveness, and over-the-counter availability,
we sought to investigate whether oral supplementation
of vitamin C would improve clinical depressive symp-
toms. Therefore, the present study was designed to
measure the effect of vitamin C on the Children’s De-
pression Rating Scale (CDRS), the Children’s Depression
Inventory (CDI), and the CGI scores in pediatric patients
with depression taking fluoxetine.Methods
Trial design
The study was a prospective, double-blind, placebo-
controlled, six-month clinical trial. Two parallel groups
of outpatient pediatric patients with depression in
Mansoura University Hospital, Egypt participated in the
study from October 2009 to September 2011. The study
was approved by the institution’s review board.Participants
The authors screened pediatric patients (less than 18 -
years of age) who were referred to the outpatient psy-
chiatry clinic for MDD based on a semi-structured
interview and DSM-IV-TR criteria [3]. Exclusion criteria
included clinically significant organic or neurological
disorder, psychotic disorder or depression with psychotic
features, a history of substance abuse or dependence, or
prior use of psychotropic medication. Young patients
with bipolar disorder may experience adverse psycho-
logical effects such as mania and hypomania due to anti-
depressants and were therefore, excluded from the
study. It has been shown that patients who are young in
age at the onset of bipolar disorder demonstrate an ill-
ness progression that is characterized by high rates of
switching into mania or hypomania in response to anti-
depressant treatment [38]. Among the 32 patients
screened during this period, five were excluded (two had
depression with psychotic features, two had a history of
hypomania, and one had a substance abuse disorder).
The remaining 27 patients agreed to participate in this
study after informed consent from at least one parent
was obtained. The patients did not receive any other
treatment such as cognitive behavioral therapy during
the trial period. This trial was performed in accordance
with the Declaration of Helsinki and subsequent revi-
sions [39]. Written consent was obtained from each pa-
tient’s parent or guardian before entering the study.
Amr et al. Nutrition Journal 2013, 12:31 Page 3 of 8
http://www.nutritionj.com/content/12/1/31Intervention
Vitamin C and placebo were formulated into capsules by
the Mansoura University Hospital. The patients were
randomly allocated to either the treatment or control
group using a computer-generated list of random num-
bers. Fourteen patients were assigned to the treatment
group and were given fluoxetine (10–20 mg/day) plus
vitamin C (1000 mg/day; 500 mg BID). Thirteen patients
were assigned to the control group and were given flu-
oxetine (10–20 mg/day) plus placebo. Patients less than
eight years of age received fluoxetine (10 mg/day),
whereas patients eight years of age or older were given
10 mg/day of fluoxetine for one week and 20 mg/day all
subsequent weeks as per the prescribing information
[40]. There are several published studies which support
the administration of 20 mg/day of fluoxetine for chil-
dren at least eight years of age [16,18,20,21], and it is
within FDA indication. The use of fluoxetine for chil-
dren under the age of eight is off-label. A dose of
1000 mg/day of vitamin C (500 mg BID) was chosen
based on human studies suggest that psychiatric patients
generally require higher levels of vitamin C to improve
symptoms than the doses that are recommended for
healthy individuals [32,41]. The recommended dose of
vitamin C for healthy individuals is 70 mg/day, while a
dose of 1000 mg/day needs to be consumed before
symptoms begin to improve in psychiatric patients [41].
Patients in the placebo group received two identical
capsules (morning and evening). No other psychotropic
medications were prescribed. Three subjects were re-
moved from the trial due to noncompliance (two pa-
tients from the vitamin C group and one from the
placebo group). Patients were assessed using CDRS, an
Arabic version of CDI, and CGI at the baseline as well
as 3 and 6 months after the start of treatment. The
scores for the CDRS were based on parent ratings, CDI
on children ratings, and CGI on clinician ratings. Exami-
nations of patients during the treatment period were
performed by a psychiatrist trained in the use of these
instruments.
Instruments
The Children’s Depression Rating Scale (CDRS) is a 16-
item measure used to determine the severity of depres-
sion in children and adolescents aged 6 to 12 [42]. The
CDRS is derived from the Hamilton Rating Scale for De-
pression (HAM-D) [43] and is based on parent, child,
and schoolteacher interviews. CDRS scores show good
concordance with research diagnostic criteria for depres-
sion [44] and correlate highly with other interview and
self-report measures of depression severity [45].
The Children’s Depression Inventory (CDI) is a 27-
item, self-rated, symptom-oriented scale suitable for
children and adolescents aged 7 to 17 [46]. The CDI issensitive to changes in depressive symptoms over time,
making it a useful index for the severity of MDD. The
CDI is reported to have high internal consistency and
test-retest reliability [47]. The CDI assessment utilized in
this study was based on the previously developed instru-
ment [46] and was translated and normalized for Arab
children by Gharib (1988) [48]. Reliability and validity
data for the Arabic version are comparable to those pro-
vided for the original instrument.
The Clinical Global Impressions Scale (CGI) is a 3-
item, observer-rated scale that measures illness sever-
ity, global improvement or change, and therapeutic
response [49]. The CGI is rated on a 7-point scale with
each component being rated separately; the instrument
does not yield a global score. Over the past 30 years,
the CGI has been shown to correlate well with stand-
ard, well-known research drug efficacy scales, including
the Hamilton Rating Scale for Depression, the Brief
Psychiatric Rating Scale, and the Scale for the Assess-
ment of Negative Symptoms across a wide range of psy-
chiatric indications [50].Statistical analysis
Student’s t-tests and chi-squared tests were used to evalu-
ate possible differences in baseline demographics. Two-
way repeated measures analysis of variance (ANOVA)
were used to assess the effects of treatment (treatment
versus placebo), time (months of visit), and an interaction
between the treatment and time. Significant differences in
the mean scores for each visit were assessed through un-
paired Student’s t-tests. Quantitative variables were tested
for normal distributions by the Kolmogorov-Smirnov test.
The variables were presented as means ± standard devia-
tions (SD). Statistical significance was set at the 5% level.
SPSS for Windows version 13 was used for the statistical
analysis of the data obtained from the study.Results
Demographic characteristics and attrition
Thirty-two patients were initially examined, but five pa-
tients did not satisfy the inclusion criteria. Therefore 27
patients enrolled in the study; 14 assigned to the vitamin
C group and 13 to the placebo group. Twenty-four pa-
tients aged between 7 and 14 completed the six-month
trial. Two patients from the vitamin C group and one
patient from the placebo group were removed from the
trial due to noncompliance (Figure 1).
The characteristics of the two study groups are sum-
marized in Table 1. The two groups were well matched,
and there were no statistically significant differences be-
tween the groups with regard to demographic factors or
duration of illness.
Figure 1 Diagram demonstrating the disposition of all patients
screened for the study.
Figure 2 Mean and SD changes in CDRS, CDI, and CGI scores at
baseline and after 3 and 6 months in fluoxetine + vitamin C
and fluoxetine + placebo groups. Asterisk indicates statistical
significance defined as P<0.05. CDI: Children’s Depression Inventory;
CDRS: Children’s Depression Rating Scale; CGI: Clinical Global
Impression; SD: standard deviation.
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The clinical severity of the depression was comparable
at baseline and not significantly different across all three
clinical instruments. As shown in Figure 2, mean scores
for CDRS, CDI, and CGI gradually improved in both
study groups during the trial. ANOVA was significantly
different on all clinical measurements (group effect, time
effect, and interaction), with the exception of group ef-
fect and interaction for CGI. The results of ANOVA are
presented in Table 2.
The most striking effects were observed for the inter-
action between treatment and time: CDRS (F=25.16,
df=1.4, 18.4, P<0.0001) and CDI (F=57.21, df=1.8, 19.8,
P<0.0001). There was no significant interaction effect in
CGI scores (F=0.68, df=1.1, 12.1, P=0.438).
The clinical changes demonstrated with vitamin C in-
take compared to placebo were noted by the third
month of the study (Table 3). At three months, a signifi-
cant difference was observed on CDRS (t=9.85,
P<0.0001) and CDI (t=10.77, P<0.0001), but not CGI
(t=0.15, P=0.88). By the end of trial (six months), the
vitamin C group showed a significantly larger decrease
in depressive symptoms compared to the placebo group
as measured by CDRS (t=11.36, P<0.0001) and CDI
(t=12.27, P<0.0001). However, the effect on CGI was not
significantly different (t=0.13, P=0.90) at six months.
Clinical complications and adverse effects
No major adverse effects were observed.
Discussion
These results show that orally administered vitamin C as
an adjunct to fluoxetine treatment leads to significantlyTable 1 Demographic data of the participants in fluoxetine +
Characteristic Vitamin C group
Age (years) 10.3 ±2.2
Sex (M/F) 7/5
Duration of illness (months) 4.3 ±1.1
Statistical significance defined as P<0.05.greater decreases in depressive symptoms in comparison
to fluoxetine treatment alone. This was demonstrated by
the decrease in depressive symptoms, which was ob-
served in the improved CDRS and CDI scores. A signifi-
cant effect was not observed for the CGI, but this may
be related to the response items for this instrument. For
instance, symptoms were scored according to whether
“much improvement” or “very much improvement” was





Table 2 Repeated-measures analysis of variance assessments at baseline and after 3 and 6 months in fluoxetine +
vitamin C and fluoxetine + placebo groups
Group effect Time effect Interaction
Variable F Df P F Df P F Df P
CDRS 155.90 1, 11 <0.0001 294.59 1.6, 17 <0.0001 25.14 1.4, 18.4 <0.0001
CDI 89.69 1, 11 <0.0001 512.77 1.8, 19.4 <0.0001 57.21 1.8, 19.8 <0.0001
CGI 0.000 1, 11 1.000 447.95 1.6, 17.2 <0.0001 0.68 1.1, 12.1 0.438
Statistical significance defined as P<0.05. CDI: Children’s Depression Inventory; CDRS: Children’s Depression Rating Scale; CGI: Clinical Global Impression.
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may have made it difficult to detect a significant im-
provement of symptoms. The differences between the
scores may have also been related to the individuals who
supplied the ratings for each instrument. More specific-
ally, the scores for the CDRS were based on parent rat-
ings, the scores for the CDI were based on children
ratings, and the scores for the CGI were based on clin-
ician ratings. The scores from the CGI were computed
based on clinical criteria such as that which is listed in
the DSM-IV-TR as well as semi-structured interviews.
Therefore, the clinician’s rating and score interpretations
adhered to strict guidelines and training, whereas the
ratings from parents and children may have been more
subjective leading to significantly different scores. None-
theless, these preliminary findings, including the results
of ANOVA suggest that vitamin C may be an effective
adjuvant agent for the treatment of depression in
pediatric patients. Furthermore, the results support the
notion that vitamin C has antidepressant-like properties
and are in accordance with previous animal research
that demonstrated vitamin C’s ability to potentiate the
action of conventional antidepressants [37].
Despite the lack of research investigating the effects of
vitamin C in pediatric patients with MDD, previous
studies have suggested that vitamin C improves clinical
symptoms in other psychiatric disorders [51-53], andTable 3 CDRS, CDI, and CGI scores at baseline and after 3 and
placebo groups
Variable Treatment duration Vitamin C group
CDRS Baseline 30.1 ±3.56
3 months 14.4 ±2.39
6 months 9.0 ±1.50
CDI Baseline 37.3 ±2.38
3 months 15.8 ±2.75
6 months 9.0 ±1.12
CGI Baseline 54.7 ±7.19
3 months 67.1 ±5.04
6 months 86.5 ±4.91
Values given are mean ± standard deviation. The statistics listed were measured wi
Inventory; CDRS: Children’s Depression Rating Scale; CGI: Clinical Global Impression.that vitamin C supplementation can be used to positively
modulate mood [33-35]. Furthermore, Khanzode et al.,
(2003) showed that plasma levels of vitamin C were de-
creased in depressive patients [54]. In a more recent
study, Chang et al., (2007) described a case in which a
patient with depression developed scurvy, suggesting
that reduced plasma levels of vitamin C due to inad-
equate vitamin C intake could be associated with the
pathophysiology of depression [29]. Other studies have
also shown that depressive symptoms are associated with
scurvy [55-57].
While the exact role of vitamin C in the etiology of
MDD is not well understood, a growing body of evi-
dence suggests that oxidative stress, characterized by an
accumulation of free radicals due to an organism’s
inhibited antioxidant capacity, may play a primary or
secondary role in the pathogenesis of neurological and
psychiatric diseases like MDD [58,59]. The brain is
much more vulnerable to oxidative free radicals than
other tissues since it utilizes 20% of the oxygen con-
sumed by the body, contains large amounts of polyun-
saturated fatty acids and iron, and typically has low
concentrations of antioxidant enzymes [60]. Previous
studies have shown that MDD may be accompanied by
disturbances in the balance between pro- and anti-
oxidative processes, demonstrated by decreased blood
plasma levels of the antioxidants enzymes superoxide6 months in fluoxetine + vitamin C and fluoxetine +
Placebo group t P
31.3 ±3.89 0.77 0.45
24.7 ±2.73 9.85 <0.0001
17.3 ±2.73 11.36 <0.0001
36.7 ±3.33 −0.42 0.68
27.0 ±2.30 10.77 <0.0001
15.5 ±1.45 12.27 <0.0001
56.3 ±7.23 0.57 0.58
67.4 ±5.55 0.15 0.88
86.7 ±4.41 0.13 0.90
th t-test. Statistical significance defined as P<0.05. CDI: Children’s Depression
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increased level of lipid peroxidation by-products in pa-
tients with depression versus healthy controls [54,61,62].
While antidepressant drugs may affect the oxidative or
antioxidative systems [54], partly due to their effects on the
immune [63] and P450 systems [64], adjunctive therapy with
vitamin C may provide additional protection as it is the
brain’s most abundant antioxidant and plays an important
role in preventing free radical-induced damage [65,66]. In
addition to its neuroprotective properties, vitamin C has also
been identified as a neuromodulator in the brain, modulat-
ing both dopamine- and glutamate-mediated neurotrans-
mission [67-69]. As there is a considerable amount of
pharmacological evidence demonstrating the efficacy of anti-
depressants with dopaminergic effects in the treatment of
depression [70], vitamin C’s complex interaction with the
dopaminergic system may be another potential mechanism
of action. However this effect appears to be dose-dependent.
Wambebe and Sokomba (1986) showed that administering
50–200 mg/kg of vitamin C to rats enhanced dopamine-
mediated behavioral effects [71], while higher dosages have
been shown to antagonize such effects [68].
There are a number of other potential biological sub-
strates that underlie vitamin C’s effects on depression
and mood. For example, Binfaré et al. [37] identified the
involvement of 5-HT1A receptors in the antidepressant-
like effect of vitamin C. Additionally, adjuvant adminis-
tration of vitamin C may also prove useful in decreasing
the risk of suicidal thoughts and behaviors linked to
antidepressant therapy in pediatric patients [72]. Meta-
analyses of placebo-controlled studies have indicated
that antidepressants may cause a significant, although
small and short-term, risk of self-harm or suicide-related
events in children and adolescents with MDD, no com-
pleted suicides were reported in any trial included in the
analysis [73,74]. Li et al. [75] reported that a history of
attempted suicide was shown to be associated with a low
level of antioxidant vitamins and carotenoids. Therefore,
increasing plasma vitamin C levels in children and ado-
lescents who are being treated with antidepressants may
help mitigate some of this risk. However, as suicidal
thoughts and behaviors were not measured in the
present study, future clinical research is needed to test
this hypothesis.
Limitations
The present study has several limitations, one being its
small sample size. While pilot clinical trials can play an
important role in the early assessment of novel treat-
ment methods when they are well designed and evalu-
ated [76], further studies with larger sample sizes are
needed to substantiate the results of this study. Sec-
ondly, drawing conclusions from a combined sample of
children and adolescents with regard to the response tomedication should be done with precaution as there is
reason to believe that children respond differently than
adolescents to antidepressants [77]. Also, due to the low
potential for adverse drug reactions related to vitamin C
in this study, the effect of doses higher than 1000 mg/
day should be considered in future studies.
Measuring plasma vitamin C levels pre- and post-
treatment may also be of interest, but although these
levels were not measured, previous studies have demon-
strated the association between hypovitaminosis C (vita-
min C deficiency) and psychological abnormalities and
this deficiency is highly prevalent in acutely hospitalized
patients [32,36]. Furthermore, the increase in plasma
and mononuclear leukocyte vitamin C from subnormal
to normal concentrations after the administration of
vitamin C administration implicate that the metabolic
properties of hypovitaminosis C are consistent with defi-
ciency as opposed to different mechanisms such as tis-
sue redistribution [36]. These findings also indicate that
patients with depression, such as those who participated
in this study, may experience vitamin C deficiency and
that the decrease in depressive symptoms that was ob-
served may be directly attributed to the synergistic anti-
depressant effect of vitamin C and fluoxetine. Future
studies that involve measuring plasma vitamin C levels
may further support these findings. Finally, in the
current study, participants were only treated and
assessed for a short period of time (six months). The
most striking effects were observed for the interaction
between treatment and time and this finding suggests
that longer trials are needed to better assess the efficacy
of vitamin C as an adjunct to fluoxetine therapy.
Conclusion
Treatment with 1000 mg/day of vitamin C potentiated
the efficacy of fluoxetine in pediatric patients being
treated for MDD. Furthermore, vitamin C was shown to
be a particularly attractive therapeutic adjuvant due to
the absence of substantial side effects and its inexpensive
cost. The observed improvements in CDRS and CDI
scores also imply that this type of treatment effectively
increases blood plasma levels of vitamin C as it has been
shown that ascorbic acid deficiency is associated with
psychological abnormalities [26-29]. Future, large-scale
clinical trials are warranted to evaluate the therapeutic
efficacy of vitamin C for the treatment of depression in
pediatric patients as well as its effectiveness as an adju-
vant treatment to antidepressants.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors participated in the preparation of the manuscript and approved
the final manuscript.
Amr et al. Nutrition Journal 2013, 12:31 Page 7 of 8
http://www.nutritionj.com/content/12/1/31Author details
1Department of Psychiatry, Mansoura University, Mansoura, Egypt.
2Biosciences Department, Global Neuroscience Initiative Foundation,
Los Angeles, California, USA. 3Neurological Institute, Cleveland Clinic,
Cleveland, Ohio, USA. 4Department of Intensive Care, Mansoura University,
Mansoura, Egypt.
Received: 11 November 2012 Accepted: 6 March 2013
Published: 9 March 2013References
1. Birmaher B, Ryan N, Williamson D, Brent D, Kaufman J, Dahl R, Perel J,
Nelson B: Childhood and adolescent depression: a review of the past
10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996, 35:1427–1439.
2. Costello E, Mustillo S, Erkanli A, Keeler G, Angold A: Prevalence and
development of psychiatric disorders in childhood and adolescence.
Arch Gen Psychiatry 2003, 60:837–844.
3. American Psychiatric Association: Diagnostic and statistical manual of mental
disorders. 4th edition. Washington, DC: American Psychiatric Association; 2000.
4. Goodyer I, Herbert J, Secher S, Pearson J: Short-term outcome of major
depression: I. Comorbidity and severity at presentation as predictors of
persistent disorder. J Am Acad Child Adolesc Psychiatry 1997, 36:179–187.
5. Hughes C, Preskorn S, Weller E, Weller R, Hassanein R, Tucker S: The effect
of concomitant disorders in childhood depression on predicting
treatment response. Psychopharmacol Bull 1990, 26:235–238.
6. Birmaher B, Arbelaez C, Brent D: Course and outcome of child and
adolescent major depressive disorder. Child Adolesc Psychiatr Clin N Am
2002, 11:619–637.
7. Lewinsohn P, Allen N, Seeley J, Gotlib I: First onset versus recurrence of
depression: differential processes of psychosocial risk. J Abnorm Psychol
1999, 108:483–489.
8. Pine D, Cohen P, Gurley D, Brook J, Ma Y: The risk for early-adulthood
anxiety and depressive disorders in adolescents with anxiety and
depressive disorders. Arch Gen Psychiatry 1998, 55:56–64.
9. Weissman M, Wolk S, Goldstein R, Moreau D, Adams P, Greenwald S, Klier C,
Ryan N, Dahl R, Wickramaratne P: Depressed adolescents grownup. JAMA
1999, 281:1707–1713.
10. Weissman M, Wolk S, Wickramaratne P, Goldstein R, Adams P, Greenwald S,
Ryan N, Dahl R, Steinberg D: Children with prepubertal-onset major
depressive disorder and anxiety grown up. Arch Gen Psychiatry 1999,
56:794–801.
11. Berton O, Nestler E: New approaches to antidepressant drug discovery:
beyond monoamines. Nat Rev Neurosci 2006, 7:137–151.
12. Holtzheimer P, Nemeroff C: Advances in the treatment of depression.
NeuroRx Journal 2006, 3:42–56.
13. Nemeroff C, Owens M: Treatment of mood disorders. Nat Neurosci 2002,
5:1068–1070.
14. Calles JJ: Depression in children and adolescents. Primary Care: Clinics in
Office Practice 2007, 34:243–258.
15. Boylan K, Romero S, Birmaher B: Psychopharmacologic treatment of
pediatric major depressive disorder. Psychopharmacology 2007, 191:27–38.
16. Emslie G, Rush A, Weinberg W, Kowatch R, Hughes C, Carmody T,
Rintelmann J: A double-blind, randomized, placebo-controlled trial of
fluoxetine in children and adolescents with depression. Arch Gen
Psychiatry 1997, 54:1031–1037.
17. Simeon J, Dinicola V, Ferguson H, Copping W: Adolescent depression: a
placebo-controlled fluoxetine treatment study and follow-up. Progress in
Neuropsychopharmacology Biological Psychiatry 1990, 14:791–795.
18. Emslie G, Heiligenstein J, Wagner K, Hoog S, Ernest D, Brown E, Nilsson M,
Jacobson J: Fluoxetine for acute treatment of depression in children and
adolescents: a placebocontrolled, randomized clinical trial. J Am Acad
Child Adolesc Psychiatry 2002, 41:1205–1215.
19. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J: Fluoxetine,
cognitive-behavioral therapy, and their combination for adolescents
with depression: Treatment for Adolescents With Depression Study
(TADS) randomized controlled trial. JAMA 2004, 292:807–820.
20. Bridge J, Jyengar S, Salary C, Barbe R, Birmaher B, Pincus H: Clinical
response and risk for suicidal ideation and suicide attempts in pediatric
antidepressant treatment. Journal of the Amercian Medical Association 2007,
297:1683–1696.21. Emslie G, Kennard B, Mayes T, Nightingale-Teresi J, Carmody T, Hughes C:
Fluoxetine versus placebo in preventing relapse of major depression in
children and adolescents. Am J Psychiatry 2008, 165:459–467.
22. Bridge J, Salary C, Birmaher B, Asare A, Brent D: The risks and benefits of
antidepressant treatment for youth depression. Ann Med 2005,
37:404–412.
23. Rosack J: New data show declines in antidepressant prescribing. Psychiatr
News 2005, 40:1.
24. Selective serotonin reuptake inhibitors: use in children and adolescents with
major depressive disorder. [http://www.mhra.gov.uk/home/groups/pl-p/
documents/drugsafetymessage/con019492.pdf].
25. Labeling change request letter. http://www.fda.gov/cder/drug/
antidepressants/SSRIlabelChange.htm.
26. Kinsman R, Hood J: Some behavioral effects of ascorbic acid deficiency.
Am J Clin Nutr 1971, 24:455–464.
27. Levine M, Conry-Cantilena C, Wang Y, Welch R, Washko P, Dhariwal K, Park
J, Lazarev A, Graumlich J, King J, Cantilena L: Vitamin C pharmacokinetics
in healthy volunteers: evidence for a recommended dietary allowance.
Proc Natl Acad Sci 1996, 93:3704–3709.
28. Milner C: Ascorbic acid in chronic psychiatric patients: A controlled trial.
Br J Psychiatry 1963, 109:294.
29. Chang C, Chen M, Wang T, Chang W, Lin C, Liu C: Scurvy in a patient with
depression. Dig Dis Sci 2007, 52:1259–1261.
30. Gan R, Eintracht S, Hoffer L: Vitamin C deficiency in a university teaching
hospital. J Am Coll Nutr 2008, 27:428–433.
31. Cocchi P, Silenzi M, Calabri G, Salvi G: Antidepressant effect of vitamin C.
Pediatrics 1980, 65:862–863.
32. Zhang M, Robitaille L, Eintracht S, Hoffer L: Vitamin C provision improves
mood in acutely hospitalized patients. Nutrition 2011, 27:530–533.
33. Brody S: High-dose ascorbic acid increases intercourse frequency and
improves mood: A randomized controlled clinical trial. Biol Psychiatry
2002, 52:371–374.
34. Kennedy D, Veasey R, Watson A, Dodd F, Jones E, Maggini S, Haskell C:
Effects of high-dose B vitamin complex with vitamin C and minerals on
subjective mood and performance in healthy males. Psychopharmacology
2010, 211:55–68.
35. Gosney M, Hammond H, Shenkin A, Allsup S: Effect of micronutrient
supplementation on mood in nursing home residents. Gerontology 2008,
54:292–299.
36. Evans-Olders R, Eintracht S, Hoffer L: Metabolic origin of hypovitaminosis C
in acutely hospitalized patients. Nutrition 2010, 26:1070–1074.
37. Binfaré R, Rosa A, Lobato K, Santos A, Rodrigues A: Ascorbic acid
administration produces an antidepressant-like effect: evidence for the
involvement of monoaminergic neurotransmission. Progress in
Neuropsychopharmacology & Biological Psychiatry 2009, 33:530–540.
38. Valentí M, Pacchiarotti I, Bonnín C, Rosa A, Popovic D, Nivoli A, Goikolea J,
Murru A, Undurraga J, Colom F, Vieta E: Risk factors for antidepressant-
related switch to mania. J Clin Psychiatry 2012, 73:e271–e276.
39. World Medical Association: World medical association declaration of
helsinki: ethical principles for medical research involving human
subjects. J Postgrad Med 2002, 48:206.
40. Highlights of Prescribing Information. http://pi.lilly.com/us/zyprexa-pi.pdf.
41. Subotičanec K, Folnegović-Šmalc V, Korbar M, Meštrović B, Buzina R: Vitamin C
status in chronic schizophrenia. Biol Psychiatry 1990, 28:959–966.
42. Poznanski E, Cook S, Carroll B: A depression rating scale for children.
Pediatrics 1979, 64:442–450.
43. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry
1960, 12:56–62.
44. Poznanski E, Grossman J, Buchsbaum Y, Banegas M, Freeman L, Gibbons R:
Preliminary studies of the reliability and validity of the Children’s
Depression Rating Scale. J Am Acad Child Psychiatry 1984, 23:191–197.
45. Shain B, Naylor M, Alessi N: Comparison of self-rated and clinician-rated
measure of depression in adolescents. Am J Psychiatry 1990, 147:793–795.
46. Kovacs M: Rating scales to assess depression in school-age children. Acta
Paedopsychiatr 1981, 46:305–315.
47. Saylor C, Finch A, Spirito A, Bennett B: The Children’s Depression
Inventory: A systematic evaluation of psychometric properties. J Consult
Clin Psychol 1984, 52:955–967.
48. Gharib A: Children’s depression inventory. Cairo: Dar Al-Nahda; 1988.
49. Guy W: ECDEU Assessment Manual for Psychopharmacology —Revised (DHEW
Publ No ADM 76–338). Rockville, MD: U.S. Department of Health, Education,
Amr et al. Nutrition Journal 2013, 12:31 Page 8 of 8
http://www.nutritionj.com/content/12/1/31and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health
Administration, NIMH Psychopharmacology Research Branch, Division of
Extramural Research Programs; 1976.
50. Brusner J, Targum S: The clinical global impressions scale: Applying a
research tool in clinical practice. Psychiatry (Edgmont) 2007, 4:28–37.
51. Dakhale GNKS, Khanzode SS, Saoji A: Supplementation of vitamin C with
atypical antipsychotics reduces oxidative stress and improves the
outcome of schizophrenia. Psychopharmacology 2005, 182:494–498.
52. Hoffer A, Osmond H: Scurvy and schizophrenia. Diseases Of The Nervous
System 1967, 24:273.
53. VanderKamp H: A biochemical abnormality in schizophrenia involving
ascorbic acid. Int J Neuropsychiatry 1966, 2:204.
54. Khanzode S, Dakhale G, Khanzode S, Saoji A, Palasodkar R: Oxidative
damage and major depression: the potential antioxidant action of
selective serotonin reuptake inhibitors. Redox Rep 2003, 8:365–370.
55. DeSantis J: Scurvy and psychiatric symptoms. Perspect Psychiatr Care 1993,
29:18–22.
56. Nguyen R, Cowley D, Muir J: Scurvy: a cutaneous clinical diagnosis.
Aust J Dermatol 2003, 44:48–51.
57. Stöger H, Wilders-Truschnig M, Schmid M, Petek W, Samonigg H: Scurvy
after a suicide attempt by starvation. Deutsche Medizinische Wochenschrift
1994, 119:589–592.
58. Ng F, Berk M, Dean O, Bush A: Oxidative stress in psychiatric disorders:
evidence base and therapeutic implications. Int J Neuropsychopharmacol
2008, 11:851–876.
59. Maes M, De Vos N, Pioli R, Demedts P, Wauters A, Neels H, Christophe A:
Lower serum vitamin E concentrations in major depression: Another
marker of lowered antioxidant defenses in that illness. J Affect Disord
2000, 58:241–246.
60. Sarandol A, Sarandol E, Eker S, Erdinc S, Vatansever E, Kirli S: Major
depressive disorder is accompanied with oxidative stress: short-term
antidepressant treatment does not alter oxidative–antioxidative systems.
Hum Psychopharmacol Clin Exp 2007, 22:67–73.
61. Bilici M, Efe H, Koroglu M, Uydu H, Bekaroglu M, Deger O: Antioxidative
enzyme activities and lipid peroxidation in major depression: alterations
by antidepressant treatments. J Affect Disord 2001, 64:43–51.
62. Ozcan M, Gulec M, Ozerol E, Polat R, Akyol O: Antioxidant enzyme
activities and oxidative stress in affective disorders. Int Clin
Psychopharmacol 2004, 19:89–95.
63. Ravindran V, Ravindran G, Sivakanesan R, Rajaguru S: Biochemical and
nutritional assessment of tubers from 16 cultivars of sweet potato
(Ipomoea batatas L.). J Agric Food Chem 1995, 43:2646–2651.
64. Stahl S: Classical antidepressants, serotonin selective reuptake inhibitors,
and noradrenergic reuptake inhibitors. In Essential Psychopharnacology.
Edited by SM S. Cambridge: Cambridge University Press; 2000:199–245.
65. Seregi A, Schaefer A, Komlos M: Protective role of brain ascorbic acid
content against lipid peroxidation. Experientia 1978, 34:1056–1057.
66. Oke A, May L, Adams R: Ascorbic acid distribution pattern in human
brain. In Third conference on Vit C. Edited by Bums J, Reverse J, Machlin L.
New York: Annals of New York Academy of Sciences; 1987:1–12.
67. Grunewald R: Ascorbic acid in the brain. Brain Res Rev 1993, 18:123–133.
68. Rebec G, Pierce R: A vitamin as neuromodulator: Ascorbate release into
the extracellular fluid of the brain regulates dopaminergic and
glutamatergic transmission. Prog Neurobiol 1994, 43:537–565.
69. Rice M: Ascorbate regulation and its neuroprotective role in the brain.
Trends Neurosci 2000, 3:209–216.
70. Papakostas G: Dopaminergic-based pharmacotherapies for depression.
Eur Neuropsychopharmacol 2006, 16:391–402.
71. Wambebe C, Sokomba E: Some behavioral and EEG effects of ascorbic
acid in rats. Psychopharmacology 1986, 89:167–170.
72. Wohlfarth T, van Zwieten B, Lekkerkerker F, Gispen-de Wied C, Ruis J,
Elferink A, Storosum J: Antidepressants use in children and adolescents
and the risk of suicide. Eur Neuropsychopharmacol 2006, 16:79–83.
73. Dubicka B, Hadley S, Roberts C: Suicidal behaviour in youths with
depression treated with new-generation antidepressants: meta-analysis.
Br J Psychiatry 2006, 189:393–398.
74. Hammad TALT, Racoosin J: Suicidality in pediatric patients treated with
antidepressant drugs. Arch Gen Psychiatry 2006, 63:332–339.75. Li Y, Zhang J: Serum concentrations of antioxidant vitamins and
carotenoid are low in individuals with a history of attempted suicide.
Nutr Neurosci 2007, 10:51–58.
76. Matthews J: Small clinical trials: are they all bad? Stat Med 1995,
14:115–126.
77. Moreno C, Roche A, Greenhill L: Pharmacotherapy of child and adolescent
depression. Child Adolesc Psychiatr Clin N Am 2006, 15:977–998.
doi:10.1186/1475-2891-12-31
Cite this article as: Amr et al.: Efficacy of vitamin C as an adjunct to
fluoxetine therapy in pediatric major depressive disorder: a randomized,
double-blind, placebo-controlled pilot study. Nutrition Journal 2013 12:31.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
